NKTX
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Nkarta, Inc. (NKTX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D+). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | C- (2.1) | C- (2.0) | D+ (1.8) | C+ (2.6) | C (2.2) |
| 2026-11-06 | C+ (2.5) | D+ (1.7) | C- (2.1) | C- (2.0) | C+ (2.7) | C (2.2) |
| 2026-10-30 | C+ (2.5) | D+ (1.7) | C (2.3) | C+ (2.6) | C+ (2.7) | C (2.3) |
| 2026-10-23 | C+ (2.5) | D+ (1.7) | C (2.3) | C (2.4) | C+ (2.6) | C (2.3) |
| 2026-10-16 | C+ (2.5) | D+ (1.7) | C (2.3) | C (2.5) | C+ (2.6) | C (2.3) |